iPSC-MNP
PreclinicalSmall molecule
iPSC-MNP is one of 40 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Amyotrophic Lateral Sclerosis
#DrugCompanyPhaseTrials
1Vimpat
UCBApproved
Nourianz
Kyowa Kirin Co., Ltd.Approved
Enablex
AbbVieApproved
Bosulif
PPrism Pharmaceuticals
Approved
Qalsody
BiogenApproved
Avodart
Akero TherapeuticsApproved
Quinidine Gluconate
WWyeth-Lederle Vaccines
Approved
Mirapex
Boehringer IngelheimApproved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iPSC-MNP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShanghai East Hospital